Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 11
Phase 21

Trial Status

Completed2

Role Distribution

Principal Investigator2
PI Rate100%

Activity Timeline

Clinical Trials (2)

NCT01131234Phase 1Completed
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
Adult Anaplastic AstrocytomaAdult Anaplastic EpendymomaAdult Anaplastic Oligodendroglioma+49 more
Principalinvestigator
NCT01260688Phase 2Completed
Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel
Hormone Refractory Prostate CancerRecurrent Prostate Cancer
Principalinvestigator

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Jeffrey Raizer, MD

Northwestern University

Related
8 trials

Shared therapeutic areas:

Adult Giant Cell GlioblastomaAdult GlioblastomaAdult Anaplastic Astrocytoma+3 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score3%

Stanislaw R. Burzynski, MD, PhD

Burzynski Research Institute

Related
62 trials

Shared therapeutic areas:

Stage IV Breast CancerRecurrent Prostate CancerStage IV Non-small Cell Lung Cancer+2 more
Similarity Score3%

Rahul Aggarwal, MD

University of California, San Francisco

Related
22 trials

Shared therapeutic areas:

Stage III Pancreatic CancerStage III Renal Cell CancerStage IV Pancreatic Cancer+1 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score2%

Ingrid Mayer, MD

Vanderbilt-Ingram Cancer Center

Related
13 trials

Shared therapeutic areas:

Stage IIIB Breast CancerStage IIIC Breast CancerStage IV Breast Cancer

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score2%

Brenda Sandmaier

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Related
12 trials

Shared therapeutic areas:

Stage IV Renal Cell CancerStage III Renal Cell Cancer

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score1%

Project Leader

Ono Pharmaceutical Co., Ltd.

Related
47 trials

Shared therapeutic areas:

Stage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung Cancer
Similarity Score1%

Norman Wolmark, MD

NSABP Foundation Inc

Related
54 trials

Shared therapeutic areas:

Stage IIIB Breast CancerStage IV Breast Cancer

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score1%

Ido Wolf, MD

Tel-Aviv Sourasky Medical Center

Related
1 trials

Shared therapeutic areas:

Stage IV Non-small Cell Lung Cancer
Similarity Score1%

Antony Magliocco, MD

Protean BioDiagnostics

Related
1 trials

Shared therapeutic areas:

Stage IV Non-small Cell Lung Cancer
Similarity Score1%

Eugenie Younger, MD

Gloucestershire Hospitals NHS Foundation Trust

Related
1 trials

Shared therapeutic areas:

Stage IV Non-small Cell Lung Cancer
Similarity Score1%

Publications (0)

No publications found for this investigator.

Clinical Trials (2)

Showing 2 of 2 trials

NCT01131234Phase 1PrincipalInvestigator

Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors

Adult Anaplastic AstrocytomaAdult Anaplastic EpendymomaAdult Anaplastic Oligodendroglioma+49 more
Completed
NCT01260688Phase 2PrincipalInvestigator

Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel

Hormone Refractory Prostate CancerRecurrent Prostate Cancer
Completed

All 2 trials loaded